Trials Sponsors Conditions Drugs Pricing

Conditions

PSVT Supraventricular Arrhythmia Supraventricular Tachycardia Supraventricular Tachycardias SVT

Keywords

Supraventricular TachycardiaCardiac ArrhythmiasCardiovascular DiseasesSVTSingle syringeSingle-syringe

Outcome Measures

Primary Outcomes (1)

First-dose successful termination of PSVT
Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.
Within 2 minutes after administration of the first dose of adenosine.

Secondary Outcomes (1)

Total administered dose of adenosine.
From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first.

Study Arms (2)

Single-syringe technique (SST)

EXPERIMENTAL

Drug: Single-syringe Adenosine

Double-syringe technique (DST)

ACTIVE COMPARATOR

Drug: Double Syringe Adenosine

Interventions

Single-syringe AdenosineDrug

Simplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 18 mL NS. A total of three doses could be provided to each patient

Single-syringe technique (SST)

Double Syringe AdenosineDrug

One Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 20 mL NS. A total of three doses could be provided to each

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age 18 to 80 years
Presentation to the emergency department with narrow-QRS tachyarrhythmia

Sponsors & Collaborators

Hormozgan University of Medical Sciences
Otherlead

Study Sites (2)

Shahid Mohammadi Hospital

Bandar Abbas, Hormozgan, Iran

Shahid Mohammadi Hospital

Bandar Abbas, Iran

MeSH Terms

Conditions

Tachycardia, SupraventricularArrhythmias, CardiacCardiovascular Diseases

Condition Hierarchy (Ancestors)

TachycardiaHeart DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Enrollment

131 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Emergency Medicine Resident

Study Record Dates

First Submitted

February 6, 2026

First Posted

April 28, 2026

Study Start

May 21, 2024

Actual (reported)

Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in PSVT

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Single-syringe technique (SST)

Double-syringe technique (DST)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Single-syringe technique (SST)

Double-syringe technique (DST)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations